Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis
March 29, 2022 07:00 ET
|
Ocuphire Pharma
Meets Primary Endpoint With 58% Of Nyxol treated Subjects Returning to Baseline Pupil Diameter at 90 Minutes Compared to 6% of Placebo Subjects (p<0.0001) MIRA-3 Confirms Prior MIRA-2 Phase 3...
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update
March 24, 2022 08:00 ET
|
Ocuphire Pharma
Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol® MIRA-3 Phase 3 Results Expected End of 1Q 2022– MIRA-4...
Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy
March 16, 2022 07:30 ET
|
Ocuphire Pharma
Successful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022 APX3330 as an Oral Therapy Has the Potential to Treat...
Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference
March 10, 2022 09:27 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
March 08, 2022 08:00 ET
|
Ocuphire Pharma
With Growing Rate of Childhood Myopia, MIRA-4 Trial Supports a Potential Broader RM Label for Nyxol in Pediatric Subjects 3 to 11 Years Ocuphire Delivering on Execution Early in 2022, Momentum Builds...
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations
February 08, 2022 08:00 ET
|
Ocuphire Pharma
Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in RM (MIRA-3) with top-line results expected soon around the end of 1Q22 VEGA-1 Phase 2 data showing the...
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day
January 31, 2022 06:00 ET
|
Ocuphire Pharma
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients...
Ocuphire to Host Virtual Investor R&D Day on January 31st
January 25, 2022 07:00 ET
|
Ocuphire Pharma
Update on Late-Stage Clinical Trials in the APX3330 and Nyxol Programs as well as Commercial Insights for Nyxol for RM and Presbyopia by Six Leading KOLs Webinar to Take Place on Monday, January 31st...
Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January
January 05, 2022 07:00 ET
|
Ocuphire Pharma
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial Initiated Enrollment of Nyxol MIRA-4 Pediatric Study in RM per Agreed Initial Pediatric Study Plan with FDA Nyxol MIRA-3 Phase 3 Results,...
Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330
December 08, 2021 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...